Waheed Yasir
Yasir Waheed, Foundation University Medical College, Foundation University Islamabad, Islamabad 46000, Pakistan.
World J Gastroenterol. 2015 Nov 21;21(43):12510-2. doi: 10.3748/wjg.v21.i43.12510.
Hepatitis C virus (HCV) is a major global health problem with high morbidity and mortality. About 185 million people are living with HCV, of which 80% are living in low and middle income countries. With the development of new highly effective treatments for HCV, it is considered that the eradication of HCV may only be one step away. The major problem with new treatment options is its high price. The price of sofosbuvir-based treatment for one patient in the United States is US$85000-110000, while the actual production cost of a 12 wk direct-acting antiviral regimen is less than US$250. Another major hindrance in HCV eradication is the lack of quality management of blood transfusion screens. Due to the lack of HCV screening, 75% of people in the United States with HCV infection are unaware of their positive HCV status. The control of massive HCV pandemic will require a significant financial investment, political will, and support from medical, pharmaceutical, and civil organizations around the globe.
丙型肝炎病毒（HCV）是一个全球性的重大健康问题，发病率和死亡率都很高。全球约有1.85亿人感染HCV，其中80%生活在低收入和中等收入国家。随着针对HCV的新型高效治疗方法的发展，人们认为根除HCV可能仅一步之遥。新治疗方案的主要问题是价格高昂。在美国，基于索磷布韦的一名患者的治疗费用为85000 - 110000美元，而一个为期12周的直接抗病毒治疗方案的实际生产成本不到250美元。根除HCV的另一个主要障碍是缺乏对输血筛查的质量管理。由于缺乏HCV筛查，美国75%的HCV感染者不知道自己的HCV检测呈阳性。控制大规模的HCV流行需要大量的资金投入、政治意愿以及全球医学、制药和民间组织的支持。
